Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kaposi Sarcoma - Drugs In Development, 2022, provides an overview of the Kaposi Sarcoma (Infectious Disease) pipeline landscape.

Kaposi's sarcoma is a cancer that causes patches of abnormal tissue to grow under the skin, in the lining of the mouth, nose, and throat or in other organs. Symptoms include patches which are usually red or purple and are made of cancer cells and blood cells. Lesions that develop in the stomach and intestines can cause abdominal pain and diarrhea.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kaposi Sarcoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Kaposi Sarcoma (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its comp...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Herpes Labialis (Oral Herpes) - Drugs In Development, 2022, provides an overview of the Herpes Labialis (Oral Herpes) (Infectious Disease) pipeline landscape.

Oral herpes is an infection of the lips, mouth, or gums due to the herpes simplex virus. Oral herpes is also called herpes labialis. Symptoms include sore throat, fever, swollen glands and painful swallowing. Treatment includes antiviral medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Herpes Labialis (Oral Herpes) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Herpes Labialis (Oral Herpes) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and la...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Respiratory Syncytial Virus (RSV) Infections - Drugs In Development, 2022, provides an overview of the Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline landscape.

Respiratory syncytial virus (RSV) infection is a respiratory disease. It infects the lungs and breathing passages. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The symptoms of RSV infection include cough, stuffy or runny nose, mild sore throat, earache and fever. Treatment includes proper medication and hygiene practice.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Respiratory Syncytial Virus (RSV) Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease), complete with analysis by stage of developme...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Multifocal Leukoencephalopathy - Drugs In Development, 2022, provides an overview of the Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline landscape.

Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the brain caused by lytic infection of oligodendrocytes by the JC polyomavirus. Symptoms include clumsiness, progressive weakness, and visual, speech, and sometimes personality changes. Risk factors include the presence of pathogenic JCV and an altered or weakened immune system, genetic or environmental factors.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Progressive Multifocal Leukoencephalopathy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Progressive Multifocal Leukoencephalopathy (Infectious Disease), complete with analysis by stage of development, drug target, mechanism o...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rubella (German Measles) - Drugs In Development, 2022, provides an overview of the Rubella (German Measles) (Infectious Disease) pipeline landscape.

Rubella also known as the German measles is an acute, contagious viral infection. The rubella virus is transmitted by airborne droplets when infected people sneeze or cough. Symptoms include fever, headache, stuffy or runny nose, inflamed, red eyes, aching joints and enlarged, tender lymph nodes at the base of the skull, the back of the neck and behind the ears.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rubella (German Measles) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Rubella (German Measles) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive ph...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Benign Prostatic Hyperplasia - Drugs In Development, 2022, provides an overview of the Benign Prostatic Hyperplasia (Male Health) pipeline landscape.

Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, a small gland that encircles the urethra in males and produces a fluid that makes up part of semen. Symptoms include decreased strength of the urine stream, dribbling after urination, pain during urination, waking at night to urinate, difficulty starting a urine stream. Treatment options for BPH include surgery and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Benign Prostatic Hyperplasia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and ...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Secondary (Hypogonadotropic) Hypogonadism - Drugs In Development, 2022, provides an overview of the Secondary (Hypogonadotropic) Hypogonadism (Male Health) pipeline landscape.

Hypogonadotropic hypogonadism (HH) is a form of hypogonadism that is due to a problem with the pituitary gland or hypothalamus. HH is caused by a lack of hormones that normally stimulate the ovaries or testes like gonadotropin-releasing hormone (GnRH), follicle stimulating hormone (FSH) and luteinizing hormone (LH). Symptoms include Lack of development at puberty, enlargement of the testes and penis, deepening of the voice, and facial hair. Treatment includes testosterone, estrogen and progesterone.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Secondary (Hypogonadotropic) Hypogonadism - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Secondary (Hypogonadotropic) Hypogo...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers - Drugs In Development, 2022, provides an overview of the Diabetic Foot Ulcers (Metabolic Disorders) pipeline landscape.

Diabetic foot ulcers are sores that occur on the feet of people with Type 1 Diabetes and Type 2 Diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg, pain, walking with difficulty, discoloration in feet: black, blue, or red, cold feet and fever, skin redness or swelling, or other signs of infection. The predisposing factors include diabetic neuropathy, peripheral vascular disease, a foot deformity and history of tobacco use disorder.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Foot Ulcers - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA),...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Neuropathy - Drugs In Development, 2022, provides an overview of the Diabetic Neuropathy (Metabolic Disorders) pipeline landscape.

Diabetic neuropathy, a common complication of diabetes, is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning and pain. The predisposing factors are obesity, hypertension, high lipid and sugar levels, smoking, etc. It may be managed by medication and dietary modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Neuropathy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Diabetic Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete ...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Retinopathy - Drugs In Development, 2022, provides an overview of the Diabetic Retinopathy (Metabolic Disorders) pipeline landscape.

Diabetic retinopathy is a complication of diabetes that affects the eyes. Diabetic retinopathy symptoms may include spots or dark strings floating in vision (floaters), blurred vision, fluctuating vision, vision loss and difficulty with color perception. The predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Retinopathy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Diabetic Retinopathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological a...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 1 Diabetes (Juvenile Diabetes) - Drugs In Development, 2022, provides an overview of the Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline landscape.

Type 1 diabetes (T1D) is an autoimmune disease in which a pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body’s immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. Risk factors of type 1 diabetes include genetics and family history, diseases of the pancreas and infection or illness. The signs and symptoms of type 1 diabetes include increased thirst and frequent urination, extreme hunger, weight loss, fatigue, irritability or unusual behavior.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Type 1 Diabetes (Juvenile Diabetes) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under developme...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 2 Diabetes - Drugs In Development, 2022, provides an overview of the Type 2 Diabetes (Metabolic Disorders) pipeline landscape.

Type 2 diabetes is a chronic condition and is the most common form of diabetes. High levels of glucose are a characteristic feature. The body might become resistant to insulin or may not produce enough amounts. Due to abnormal insulin functioning, glucose is concentrated in the blood leading to elevated levels and hence causing type 2 diabetes. Symptoms include fatigue, weight issues, vision deficits and various other effects. Risk factors include family history, age, obesity, physical inactivity and high blood pressure. This condition is handled by lifestyle alterations and regular medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Type 2 Diabetes - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Type 2 ...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypercholesterolemia - Drugs In Development, 2022, provides an overview of the Hypercholesterolemia (Metabolic Disorders) pipeline landscape.

Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood. This leads in formation of sticky deposits (called plaque) along the artery walls. Plaque can completely block blood flow through an artery, causing heart attack or stroke. Two forms of the condition exist heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH). Risk factors include obese, family history, high blood pressure, smoking and diabetes. Treatment includes statins, bile acid sequestrants, fibric acid derivatives and cholesterol absorption inhibitors

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypercholesterolemia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under de...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Heterozygous familial hypercholesterolemia (heFH) - Drugs In Development, 2022, provides an overview of the Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) pipeline landscape.

Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder caused due to a mutation (alteration) of FH from one (affected) parent. Symptoms include xanthesmas, corneal arcus, aortic rupture and peripheral vascular disease. Risk factors include age, sex, smoking and hypertension, or associated lipid abnormalities such as low HDL-C levels, high TG levels, or presence of type III dyslipoproteinemia.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Heterozygous familial hypercholesterolemia (heFH) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders), complete with analysis...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Obesity - Drugs In Development, 2022, provides an overview of the Obesity (Metabolic Disorders) pipeline landscape.

Obesity is defined as having an excessive amount of body fat. Obesity increases risk of diseases and health problems such as heart disease, diabetes and high blood pressure. The predisposing factors include age, family history, quitting smoking, lack of sleep and certain medications. Treatment includes healthy lifestyle, medications and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Obesity - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development his...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gingivitis - Drugs In Development, 2022, provides an overview of the Gingivitis (Mouth And Dental Disorders) pipeline landscape.

Gingivitis is an inflammation of the gums, usually caused by a bacterial infection. Symptoms include sensitive teeth, pus between teeth and gums, loose teeth, gums that are red, tender, or swollen. Risk factors include diabetes, smoking or chewing tobacco, broken fillings, compromised immunity, and genetic factors. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gingivitis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Gingivitis (Mouth And Dental Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete r...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ankylosing Spondylitis (Bekhterev's Disease) - Drugs In Development, 2022, provides an overview of the Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline landscape.

Ankylosing spondylitis is a type of arthritis that affects the spine. Ankylosing spondylitis symptoms include pain and stiffness from the neck down to the lower back. The spine's bones (vertebrae) may grow or fuse together, resulting in a rigid spine. These changes may be mild or severe, and may lead to a stooped-over posture.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ankylosing Spondylitis (Bekhterev's Disease) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), r...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Axial Spondyloarthritis - Drugs In Development, 2022, provides an overview of the Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline landscape.

Axial spondylitis is a type of inflammatory arthritis involving the spine and/or sacroiliac joints. Axial spondylitis is strongly related to the presence of the HLA-B27 gene. A genetic test for HLA-B27 is available.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Axial Spondyloarthritis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Axial Spondyloarthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Axia...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Psoriatic Arthritis - Drugs In Development, 2022, provides an overview of the Psoriatic Arthritis (Musculoskeletal Disorders) pipeline landscape.

Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis. Symptoms include swollen fingers and toes, foot pain and lower back pain. Risk factors include age, family history and psoriasis. Treatment includes NSAIDs, immunosuppressants and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Psoriatic Arthritis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Psoriatic Arthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and la...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Muscular Dystrophy - Drugs In Development, 2022, provides an overview of the Muscular Dystrophy (Musculoskeletal Disorders) pipeline landscape.

Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Muscular Dystrophy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gouty Arthritis (Gout) - Drugs In Development, 2022, provides an overview of the Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline landscape.

Gout is a type of arthritis where swelling and severe pain develops in joints, especially at the base of the big toe. Gout occurs when uric acid builds up in blood and causes inflammation in the joints. Symptoms include sudden onset of joint pain, joint swelling, heat in the affected area and joint redness. Risk factors include obesity, high alcohol intake, injury to a joint, long-standing kidney disease and high intake of foods rich in purines.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gouty Arthritis (Gout) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action ...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteonecrosis - Drugs In Development, 2022, provides an overview of the Osteonecrosis (Musculoskeletal Disorders) pipeline landscape.

Osteonecrosis is bone death caused by poor blood supply to the area. It is most common in the hip and shoulder, but can affect other large joints such as knee, elbow, wrist and ankle. Osteonecrosis can be caused by disease, or a severe trauma, such as a break or dislocation, that affects the blood supply to the bone. There are no symptoms in the early stages. Symptomatic treatment is available.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteonecrosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Osteonecrosis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pigmented Villonodular Synovitis - Drugs In Development, 2022, provides an overview of the Pigmented Villonodular Synovitis (Musculoskeletal Disorders) pipeline landscape.

Pigmented villonodular synovitis (PVNS) is a condition that causes the synovium. PVNS is characterized by inflammation and overgrowth of the joint lining. This affects the hip or knee. Symptoms include pain, swelling in the affected joint, locking, catching, and instability in the joint. Treatment includes surgery and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pigmented Villonodular Synovitis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Pigmented Villonodular Synovitis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide cover...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dermatomyositis - Drugs In Development, 2022, provides an overview of the Dermatomyositis (Musculoskeletal Disorders) pipeline landscape.

Dermatomyositis is a rare inflammatory disease which is characterized by chronic muscle inflammation accompanied by muscle weakness. Symptoms of dermatomyositis include a distinctive skin rash, muscle weakness, and inflammatory myopathy, or inflamed muscles. Risk factors include age and gender. Treatment includes corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dermatomyositis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Dermatomyositis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete ...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Drugs In Development, 2022, provides an overview of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline landscape.

Acute lymphocytic leukemia (ALL) is the cancer of the white blood cells due to the production of a large number of immature lymphocytes thus blocking the production of normal blood cells. It enters the blood stream and rapidly progress to other parts of the body such as spleen, lymph nodes and liver. Risk factors for ALL include exposure to radiation or chemicals, age, virus infections and genetic factors. Symptoms include anemia, frequent infections, easy bruising, bone pain and breathing problems. Treatment includes chemotherapy, transfusions, transplant and medications.c

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Drug...